Goldman Sachs raised its rating on Bruker Corporation BRKR from Neutral to Buy and raised its price target from $13 to $19.
Goldman Sachs commented, "We upgrade shares of Bruker (BRKR) to Buy from Neutral and raise our 12-month price target to $19 (from $13), which implies 40% upside. After underperforming Tools peers by 1000bp YTD, we see a turnaround story for 2013 with healthy organic growth, margin expansion, and an attractive risk/reward profile coupled with the following catalysts: (1) better-than-expected strength in core end markets, (2) pending detail on long-term margin expansion plans, and (3) low expectations/valuation that sets up a “laggards to leader” trade."
Bruker Corporation closed at $13.61 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in